GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Net Income

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Net Income : $0.09 Mil (TTM As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Parnell Pharmaceuticals Holdings's Net Income for the six months ended in Dec. 2018 was $0.09 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2018 was $0.09 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Parnell Pharmaceuticals Holdings's Earnings per Share (Diluted) for the six months ended in Dec. 2018 was $0.01.


Parnell Pharmaceuticals Holdings Net Income Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Net Income Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Net Income
Get a 7-Day Free Trial -16.23 -9.96 -15.94 -17.68 0.09

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Net Income Get a 7-Day Free Trial -16.23 -9.96 -15.94 -17.68 0.09

Parnell Pharmaceuticals Holdings Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Parnell Pharmaceuticals Holdings's Net Income for the fiscal year that ended in Dec. 2018 is calculated as

Net Income(A: Dec. 2018 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=0.242+-0.148+0+-0.001
=0.09

Parnell Pharmaceuticals Holdings's Net Income for the quarter that ended in Dec. 2018 is calculated as

Net Income(Q: Dec. 2018 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=0.242+-0.148+0+-0.001
=0.09

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income for the trailing twelve months (TTM) ended in Dec. 2018 was $0.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Parnell Pharmaceuticals Holdings  (OTCPK:PARNF) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Parnell Pharmaceuticals Holdings's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2018 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Parnell Pharmaceuticals Holdings Net Income Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.